Buy Like Buffett
Watchlist

Flagship explainer

How ORAMED PHARMACEUTICALS INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$2M · 100%Cost of revenue$2M · 99%Gross profit$13000 · 1%Operating income−$15.1M · −754%Income before tax$75.3M · 3766%Income tax$11.3M · 565%Net income$64M · 3203%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$2M100%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
Cost of revenue$2M99%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
$130001%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
−$15.1M−754%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
Income before tax$75.3M3766%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
Income tax$11.3M565%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
$64M3203%
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001213900-26-034835 · filed Mar 26, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full ORAMED PHARMACEUTICALS INC. analysis at Buy Like Buffett